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http://www.lipidworld.com/content/14/1/3RESEARCH Open AccessDietary supplementation with arachidonic acid
increases arachidonic acid content in paw, but
does not affect arthritis severity or prostaglandin
E2 content in rat adjuvant-induced arthritis model
Norifumi Tateishi1,2*, Yoshihisa Kaneda1, Saki Kakutani1, Hiroshi Kawashima1, Hiroshi Shibata1 and Ikuo Morita3Abstract
Background: Arachidonic acid (ARA) is an essential fatty acid and a major constituent of biomembranes. It is
converted into various lipid mediators, such as prostaglandin E2 (PGE2), which is involved in the development of
rheumatoid arthritis (RA). However, the effects of dietary ARA on RA are unclear. Our objective was to clarify the
effects of dietary ARA on an experimental rat arthritis model.
Methods: Lew rats were fed three contents of ARA diet (0.07%, 0.15% or 0.32% ARA in diet (w/w)), a docosahexaenoic
acid (DHA) diet (0.32% DHA), or a control diet. After 4 weeks, arthritis was induced by injection of Freund’s complete
adjuvant into the hind footpad. We observed the development of arthritis for another 4 weeks, and evaluated arthritis
severity, fatty acid and lipid mediator contents in the paw, and expression of genes related to lipid mediator formation
and inflammatory cytokines. Treatment with indomethacin was also evaluated.
Results: The ARA content of phospholipids in the paw was significantly elevated with dietary ARA in a dose-dependent
manner. Dietary ARA as well as DHA did not affect arthritis severity (paw edema, arthritis score, and bone erosion).
PGE2 content in the paw was increased by arthritis induction, but was not modified by dietary ARA. Dietary ARA did
not affect the contents of other lipid mediators and gene expression of cyclooxygenase (COX)-1, COX-2, lipoxgenases
and inflammatory cytokines. Indomethacin suppressed arthritis severity and PGE2 content in the paw.
Conclusion: These results suggest that dietary ARA increases ARA content in the paw, but has no effect on arthritis
severity and PGE2 content of the paw in a rat arthritis model.
Keywords: Arachidonic acid, Arthritis, Prostaglandin E2, Lipoxin A4Introduction
Polyunsaturated fatty acids (PUFAs), such as arachidonic
acid (ARA) and docosahexaenoic acid (DHA), are natural
nutrients present in common foodstuffs (e.g., egg yolk,
meat, and fish oil) and are physiologically important
constituents of biomembranes. ARA is an n-6 fatty acid
and is converted from Linoleic acid (LA) in vivo. ARA
also acts as the substrate for various lipid mediators,
such as prostaglandins (PGs), leukotrienes, lipoxins* Correspondence: Norifumi_Tateishi@suntory.co.jp
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unless otherwise stated.(LX), endocannabinoids, and epoxyeicosatetranoates
[1-3]. The recent studies demonstrated that the conver-
sion ability from LA to ARA was decreased with aging
[4] and that dietary ARA supplementation improved
cognitive response [5,6] and cardiovascular function
[7,8] in the elderly people and aged rats.
It has been clarified that dietary ARA affects the ARA
content of phospholipids in humans and animals [9-14].
An ex vivo study using cells prepared from animals in
which dietary fatty acid intake was manipulated showed
that different diets impacted the production of PGs and
leukotrienes [15-18]. We reported that ARA supplemen-
tation in healthy Japanese elderly individuals increased
plasma ARA but did not increase ARA-derived lipidl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Fatty acid composition of the diets
Fatty acids CON ARA(L) ARA(M) ARA(H) DHA
g/100 g fatty acids
16:0 palmitic acid 27.1 28.0 28.1 27.4 28.3
18:0 stearic acid 4.4 4.7 4.8 5.1 4.6
18:1(n-9) oleic acid 32.0 32.2 31.4 29.5 30.7
18:2(n-6) linoleic acid 23.4 20.9 19.1 15.8 21.3
18:3(n-3) α-linolenic
acid
11.6 10.8 10.9 11.6 2.5
20:3(n-6) dihomo-γ-linolenic
acid
0.0 0.1 0.3 0.6 0.0
20:4(n-6) arachidonic acid 0.0 1.4 2.9 6.3 0.5
20:5(n-3) eicosapentaenoic
acid
0.0 0.0 0.0 0.0 1.6
22:6(n-3) docosahexaenoic
acid
0.0 0.0 0.0 0.0 6.3
Others 1.5 1.9 2.5 3.7 4.2
Total 100 100 100 100 100
PUFA 35.7 34.0 34.1 35.5 33.4
MUFA 32.6 32.6 31.9 30.0 33.6
SFA 31.8 33.4 34.1 34.5 33.0
n-6/n-3 2.0 2.1 2.0 2.0 2.2
Fatty acid composition of the experimental diets. Numbers in the table are
expressed in percent except for the n-6/n-3 ratio. PUFA: polyunsaturated fatty
acid; MUFA: monounsaturated fatty acid; SFA: saturated fatty acid. Note that
each diet comprised equa.
Tateishi et al. Lipids in Health and Disease 2015, 14:3 Page 2 of 11
http://www.lipidworld.com/content/14/1/3mediators or clinical parameters, including inflammatory
parameters such as C-reactive protein, interleukin-6 (IL-6),
and tumor necrosis factor-α (TNF-α) [12]. We recently
studied the effects of dietary ARA on acute inflamma-
tion and reported that dietary ARA increased the ARA
and LXA4 contents in the colon but did not affect the
severity of inflammation or PGE2 content in a murine
colitis model [14].
Rheumatoid arthritis (RA) is one of the major auto-
immune diseases and is associated with chronic inflamma-
tion of the joints and bones. Biological disease-modifying
antirheumatic drugs are frequently recommended for
RA therapy, indicating that inflammatory cytokines are
important molecules in the pathology of RA [19-21].
Non-steroidal anti-inflammatory drugs (NSAIDs) and
cyclooxygenase (COX) inhibitors are no longer first-line
drugs for RA, but before the advent of biologic therapy,
these agents were widely used for RA because lipid me-
diators produced from ARA by COX, such as PGE2, are
involved in the development of RA [22,23]. Therefore,
ARA metabolism is still important in the treatment of
RA, but the effects of dietary ARA on chronic inflam-
mation, such as RA, are not fully understood.
In the present study, to clarify the effects of dietary
ARA on chronic inflammation and PGE2 status, we eval-
uated the effects of ARA at various doses on the severity
of an adjuvant-induced arthritis (AIA) model in rats,
and determined the contents of ARA and ARA-derived
lipid mediators and the expression of genes related to
these lipid mediators and inflammatory cytokines.
Materials and methods
Animals, diets, and experimental design
Experiments were approved by the Animal Care and Use
Committee of Suntory Holdings Ltd. (Osaka, Japan), and
we followed the Guidelines for Animal Care and Use of
Suntory Holdings Ltd. Seventy 4-week-old male Lew rats
were obtained from Charles River Japan (Yokohama, Japan).
Rats were housed under standard conditions and had
free access to water and diet.
We used five types of diet based on the AIN-76 rodent
diet (Table 1). The AIN-76 contains 5% fat in diet and
the composition of the diets was the same as that of
AIN-76, except for lipids in this study. In brief, AIN-76
rodent diet was composed of 20% casein, 43% corn-
starch, 12% alpha-type cornstarch, 10% sucrose, 5% fat,
5% cellulose fiber, 3.5% AIN-76 salt mix, 1.0% AIN-76
vitamin mix, 0.3% dl-methionine and 0.2% choline bitar-
trate. The lipids used in the present study were ARA-
enriched triacylglycerol (SUNTGA40S) (lot no. 100120A1;
Nippon Suisan Kaisha Ltd., Tokyo, Japan), fish oil (DHA-
27 W) (lot no. 1003251; Maruha Nichiro Food Corporation
Ltd., Tokyo, Japan), and palm oil, soybean oil, and linseed
oil (Showa Kousan Ltd., Osaka, Japan). The ARA contentwas approximately 42.5% in ARA-enriched triacylglycerol,
which was used in diets for the low dose of ARA (ARA
(L)), the medium dose of ARA (ARA(M)), and the high
dose of ARA (ARA(H)) groups. DHA and eicosapenta-
enoic acid (EPA) contents were approximately 26.8 % and
6.8%, respectively, in fish oil, which was used in the diet
for the DHA groups. Control diet (CON) had no ARA,
DHA and EPA. Palm oil, soybean oil, and linseed oil
contained no ARA, DHA, or EPA, and were used to
adjust the amounts of total lipids, total saturated fatty
acids (S), total monounsaturated fatty acids (M), total
polyunsaturated fatty acids (P), total n-6 fatty acids,
and total n-3 fatty acids to similar levels in the five
diets, respectively (Table 1). Experimental diets were
stored at 4°C and protected from light to prevent
oxidation.
Induction and evaluation of AIA
After a 1-week acclimation period, rats were randomly
assigned to seven groups of 10 rats according to body
weight, and received one of the five diets described above
for 8 weeks (Figure 1). Arthritis was induced by subcuta-
neous injection of 0.05 mg of Mycobacterium butyricum
(Difco Laboratories Inc., Detroit, MI) suspended in
0.1 mL of liquid paraffin into the left hind footpad on
Figure 1 Experimental procedure for rat adjuvant-induced arthritis model in the present study.
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nipulation started). The dose of M. butyricum was de-
signed to induce a moderate degree of arthritis for
detecting both the promotion and suppression of arth-
ritis by diet or indomethacin (Additional file 1: Table
S1). Liquid paraffin without M. butyricum was injected
in group 1. Indomethacin (1 mg/kg body weight) sus-
pended in 0.1% carboxymethyl cellulose was orally ad-
ministered once daily from day 29 to day 56 in group
7. Body weight and hind-paw swelling were measured
intermittently. The volumes of the ipsilateral (left) and
contralateral (right) hind paws were measured using a
plethysmometer (Unicom, Chiba, Japan) before adju-
vant injection (day 29) and on days 36, 43, 50, and 57.
The severity of arthritis symptoms in the whole body
was graded according to Yamaguchi et al. [24], with
minor modification. In brief, the clinical severity of
arthritis was scored as follows: 0 – normal; 1 – very slight;
2 – slight; 3 – moderate; 4 – marked and 5 – strong. The
cumulative clinical arthritis score per rat was the total of
five individual scores for ears, tail, forelimbs, ipsilateral
hind paw and contralateral hind paw, with a maximum
score of 25. At the end of the experiments, rats were anes-
thetized with isoflurane and killed via blood sampling
from the abdominal aorta and exsanguination. Knee and
ankle joints of the contralateral paw were fixed with 10%
neutral buffered formalin and used for radiography ana-
lysis. The X-ray score was defined according to Fukawa
et al. [25] as the total score of a combination of osteo-
penia, bone erosion, and new bone formation as fol-
lows: 0 – no change; 1 – slight change, 2 – moderate
change; and 3 – severe change. The ipsiralateral hind paw
was immediately frozen in liquid nitrogen and used for ana-
lyses of fatty acids, lipid mediators, and gene expression.
Fatty acid analysis
Lipids in the diets, paws, and plasma were extracted and
purified by the method of Folch et al. [26]. Lipids in thepaw and plasma were separated into phospholipids (PL)
and other lipid fractions by thin-layer chromatography
using silica gel 60 (Merck, Darmstadt, Germany). The
solvent system consisted of hexane/diethyl ether (7/3, v/v).
Fatty acid residues in extracted lipids or separated phos-
pholipids were analyzed by the method of Sakuradani
et al. [27]. Briefly, each lipid fraction was incubated with an
internal standard (pentadecanoic acid) in methanolic HCl
at 50°C for 3 h to transmethylate fatty acid residues to fatty
acid methyl esters, which were extracted with n-hexane
and analyzed by capillary gas–liquid chromatography.
Analysis of lipid mediators of footpad homogenates
PGE2, PGE2-d4, leukotriene B4 (LTB4), LTB4-d4, LXA4,
and LXA4-d5 were obtained from Cayman Chemical
(Ann Arbor, MI). The methods for extraction and analysis
of lipid mediators were reported previously [28,29]. Briefly,
footpad tissue frozen in liquid nitrogen was ground using
a Multi-Beads Shocker MB701(S) (Yasui Kikai, Osaka,
Japan) and homogenized with ice-cold ethanol. A fixed
amount of PGE2-d4, LTB4-d4, and LXA4-d5 was added
to all homogenates as an internal standard. After centrifu-
gation, each supernatant was dried by centrifugal evapor-
ation, and residues were dissolved in methanol, washed,
and concentrated with SPE cartridges (Empore disk cart-
ridge C18 SD; 3 M, St. Paul, MN). An Agilent 1200 HPLC
system (Agilent Technologies, Santa Clara, CA) equipped
with a Cadenza CD-C18 column (3 mm, 2 mm i.d. ×
150 mm; Imtakt, Kyoto, Japan) and quadruple linear
ion trap hybrid mass spectrometer, 4000 Q TRAP, with
an electrospray interface (Applied Biosystems/MDS
SCIEX, Concord, Canada) was used for quantification.
The mass spectrometer was operated in negative ion
mode with selected reaction monitoring. PGE2 and
PGE2-d4 were detected by monitoring mass transitions
at m/z 351→ 271 for PGE2 and m/z 355→ 275 for
PGE2-d4 at a collision energy of −24 V. The quantita-
tive range of PGE2 was 0.3 – 100 ng/injection. LTB4
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tions at m/z 335→ 195 for LTB4 and m/z 339→ 197
for LTB4-d4 at a collision energy of −24 V. The quanti-
tative range of LTB4 was 0.6 – 200 pg/injection. LXA4
and LXA4-d5 were detected by monitoring mass tran-
sitions at m/z 351→ 115 for LXA4 and m/z 356→ 115
for LXA4-d5 at a collision energy of −22 V. The quantitative
range of LXA4 was 3 – 1000 pg/injection.
Quantitative real-time polymerase chain reaction
(QRT-PCR)
The methods for QRT-PCR were as reported previously
[30], with some modification. In brief, the total RNA
from hind-footpad tissues stored at −80°C was extracted
using Isogen (Nippon Gene Co., Ltd., Toyama, Japan)
and purified with an RNeasy mini kit (Qiagen GmbH,
Hilden, Germany). The total RNA (2.0 μg) was reverse-
transcribed with random primers using High-Capacity
cDNA Reverse Transcription Kits (Applied Biosystems,
Foster City, CA) in accordance with the recommenda-
tions of the manufacturer. To quantify the gene expres-
sion, cDNA was amplified for various gene targets by
QRT-PCR using the ABI PRISM 7900 Sequence Detection
System (Applied Biosystems). All primers and probes used
were purchased as TaqMan Gene Expression Assays: cyto-
solic phospholipase A2 (cPLA2, Rn00591916_m1), COX-1
(Rn00566881_m1), COX-2 (Rn01483828_m1), arachido-
nate 5-lipoxygenase (5-LOX, Rn00563172_m1), arachido-





































































Figure 2 Fatty acid composition of phospholipids ((a) ARA, (b) LA, (c)
induced arthritis rats. Data are means ± SD. *p < 0.05, **p < 0.01 versus ATNF-α (Rn01525859_g1), IL-1beta (Rn0058432_m1), IL-6
(Rn01410330_m1) and IL-10 (Rn00566881_m1) (Applied
Biosystems). PCR results were analyzed with ABI SDS
software (Applied Biosystems). Relative expression
levels of the genes in each sample were determined by
the Comparative Ct Method. Expression assays for each
gene were normalized against glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, Rn01775763_g1) and expressed
as fold change relative to that of the disease-control group
(group 2).
Statistical analysis
Data are presented as means ± SD. Data were analyzed
by the unpaired two-tailed t test or one-way analysis of
variance followed by Dunnett or Steel multiple compari-
sons. Correlation analyses were performed using the
Spearman correlation test. P < 0.05 was considered sta-
tistically significant.
Results
Fatty acid content of the hind-paw and plasma
Figure 2 shows the fatty acid content of the phospho-
lipids of the ipsilateral hind-paw. ARA was significantly
higher and DHA was significantly lower in paws of the
adjuvant-treated CON diet group (ADV+/CON, group
2) compared with those of the adjuvant-untreated CON
diet group (ADV-/CON, group 1) (Figure 2a). Dietary
ARA significantly increased the ARA content of paws in





































































DHA, and (d) EPA) in the ipsilateral hind paw from adjuvant-
DV+/CON diet group (n = 10 per group).
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20.7 ± 0.7% and 23.9 ± 0.9%, respectively. Dietary ARA
inversely decreased linoleic acid (LA), DHA, and EPA
contents of paws in an ARA dose-dependent manner
(Figure 2b, c, d). In the ADV+/DHA group (group 6),
the DHA content was high (3.3 ± 0.2%) and the ARA
content was low (18.5 ± 1.1%) compared to the ADV+/CON
group (DHA content, 1.6 ± 0.2%; and ARA content,
20.7 ± 0.7%). In the adjuvant- and indomethacin- treated
CON diet group (ADV+/CON+ IM group, group 7), ARA
was lower and LA and DHA were higher in paws com-
pared with those of the ADV+/CON group. A similar ten-
dency was observed for plasma phospholipids (Additional
file 2: Figure S1a, b, c, d). Dietary ARA significantly in-
creased the ARA content of plasma in a dose-dependent
manner. Total n-6 and n-3 contents and n-6/n-3 ratio
in phospholipids of paws and plasma are shown in
Additional file 3: Figure S2a-f. In the paw, total n-3
was lower and n-6/n-3 ratio was higher in the ARA
diet groups, and total n-3 was higher and total n-6 and
n-6/n-3 ratio was lower in the DHA diet group com-
pared with ADV+/CON group. Similar tendency was
observed in plasma.
Effects of dietary ARA on AIA symptoms
Body weight was not different between groups before
AIA induction, but was higher in the ADV-/CON and
ADV+/CON + IM groups than in the ADV+/CON group
on days 50 and 57. Dietary ARA or DHA did not affect
body weight through the experiment (Additional file 4:
Figure S3). Adjuvant injection induced a moderate and
significant paw edema in the ipsilateral side (on day 50:
the ADV+/CON group, 3.4 ± 0.5 ml; and the ADV-/
CON group; 2.5 ± 0.1 ml) (Figure 3a). The volumes of





























Figure 3 Time course of adjuvant-induced paw edema in ipsilateral (a
diet (ARA(L), ARA(M) or ARA(H)), DHA diet, or control diet (CON) from day 0
containing 0.05 mg of M. butyricum (ADV+) or without M. butyricum (
indomethacin (1mgkg−1) once a daily from day 29 to day 56. Data are
(n = 10 per group).not different from those in the ADV+/CON group. The
volume of ipsilateral paws was significantly suppressed
in the ADV+/CON + IM group. Adjuvant injection also
seemed to induce moderate paw edema in the contralat-
eral side (on day 50: the ADV+/CON group, 2.5 ± 0.4 ml;
the ADV-/CON group, 2.1 ± 0.1 ml), but differences were
not significant (Figure 3b). No effects of diets or indo-
methacin were observed in contralateral paw volume.
The systemic arthritis score was significantly increased
after arthritis induction and reached 8.6 ± 4.5 on day 50 in
the ADV+/CON group (0.7 ± 0.5 in the ADV-/CON
group) (Figure 4). Arthritis scores in the groups fed ARA
or DHA were not different from those in the ADV+/CON
group. Arthritis scores were significantly suppressed in the
ADV+/CON+ IM group. Moderate bone damage seemed
to be induced (the ADV+/CON group, 1.5 ± 1.7; and the
ADV-/CON group, 0), but differences were not significant
(Figure 5). No effects of diets or indomethacin were
observed in bone damage score.
Lipid mediator and gene expression
Arthritis induction significantly increased the PGE2 content
of the paw (the ADV+/CON group, 15.0 ± 17.5 pg/mg tis-
sue wet weight; and the ADV-/CON group; 1.8 ± 2.5 pg/mg
tissue wet weight) (Figure 6a). The PGE2 content of
paws in groups fed ARA or DHA were not different
from that in the ADV+/CON group. Indomethacin
treatment significantly suppressed the PGE2 content of
the paw. The content of LXA4 (the ADV+/CON group;
0.13 ± 0.1 pg/mg tissue wet weight; and the ADV-/CON
group, 0.05 ± 0.1 pg/mg tissue wet weight) and LTB4
(the ADV+/CON group; 0.81 ± 0.46 pg/mg tissue wet
weight; and the ADV-/CON group, 0.24 ± 0.16 pg/mg
tissue wet weight) seemed to increase with arthritis induc-


















) and contralateral hind paws (b). Rats were fed three types of ARA
. Adjuvant arthritis was induced by subcutaneous injection of adjuvant
ADV-) on day 29. Rats in the IM group were orally administered
































Figure 4 Time course of the arthritis score. The score was
determined as described in Materials and methods. Data are means
± SD. **p < 0.01 versus ADV+/CON diet group (n = 10 per group).
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LXA4 and LTB4. To elucidate the relationship between the
ARA content and PGE2 content in the paw and paw vol-
ume, we analyzed the correlation of these parameters in
the adjuvant- and ARA-treated groups (groups 2–5). As
shown in Figure 7, we detected no correlation of ipsiralat-
eral paw volume or paw PGE2 content with the ARA con-
tent in the paw (Figure 7a and b), paw PGE2 content with
ipsiralateral paw volume (Figure 7c).
We assayed the expression of genes related to lipid
mediator formation, such as cPLA2, COX-1, COX-2,
5-LOX, and 12/15-LOX (Additional file 5: Figure S4 a-e).
Only COX-1 expression in the ADV-/CON group was sig-
nificantly lower than that in the ADV+/CON group, but
no other gene expressions differed between the ADV- and
ADV+/CON groups. The ARA or DHA diet had no effect
on these gene expressions. Indomethacin treatment in-
creased only ALOX5 gene expression. In addition, to de-





























Figure 5 Bone erosion score for the joint of the contralateral
hind paws from adjuvant-induced arthritis rats. At the end of
the experiments, knee and ankle joints of the contralateral paw were
fixed with 10% neutral buffered formalin and X-ray score was
defined as described in Materials and Methods. Data are means ± SD
(n = 10 per group).to inflammation, we also analyzed gene expression of IL-
1beta, IL-6, TNF-α, and IL-10. There were no differences
between these groups in these genes (Additional file 6:
Figure S5 a-d).
Discussion
In the present study, dietary ARA supplementation sig-
nificantly increased the ARA content in the inflamed
paw in a dose-dependent manner, but did not affect the
severity and content of lipid mediators in an AIA rat
model. This is the first study to demonstrate the effect
of dietary ARA on AIA in rats.
Some studies have reported that dietary n-6 fatty acids,
mainly LA, exacerbated the symptoms of arthritis models
compared to n-3 fatty acids [31-34]. It might be believed
that dietary ARA also exacerbates arthritis because ARA
is the major n-6 PUFA in the body and is converted to
various proinflammatory lipid mediators. However, it re-
mains unknown whether dietary ARA itself exacerbates
arthritis or not. To detect the effect of ARA accurately, we
carefully designed the experimental conditions and ad-
justed the severity of AIA to moderate levels (Additional
file 1: Table S1). Therefore we could detect both suppres-
sion and exacerbation of AIA if ARA had such potential
and aimed to prevent a false-negative misjudgement of
the potential of ARA. In the present study, dietary ARA
significantly increased ARA in phospholipids of the in-
flamed paw and plasma in a dose-dependent manner in
AIA (Figure 2 and Additional file 2: Figure S1), which is
consistent with previous studies in humans [9-12] and an-
imals [13-15]. Despite local and systemic increases in
ARA, dietary ARA did not exacerbate any AIA parame-
ters, such as paw edema, arthritis score, or bone erosion.
Our data in this study are supported by the previous pa-
pers. Severity of murine colitis, a typical acute bowel in-
flammatory model, was also unchanged by dietary ARA
[14]. Conversely, there was a report that ARA ethyl ester
improved some parameters (body weight loss and diar-
rhea) in a similar colitis model [35]. A human study re-
vealed that dietary ARA did not affect inflammatory
parameters (plasma CRP, IL-6, and TNF-α) in healthy par-
ticipants [12]. Ultimately, there has been a lack of infor-
mation regarding whether dietary ARA exacerbates the
severity of the inflammatory diseases. The present results
suggest that dietary ARA did not affect chronic inflamma-
tory diseases like arthritis, as well as acute inflammatory
diseases in previous studies mentioned above. Further-
more, interestingly, ARA content in ADV+/CON group
was higher and DHA content in this group was lower
compared with ADV-/CON group (Figure 2). Similar ten-
dency was observed in plasma (Additional file 2: Figure
S1). Total n-6 and n-3 contents also showed the similar
tendency (Additional file 3: Figure S2). The animals in

















































































































Figure 6 Prostaglandin E2 (PGE2), lipoxin A4 (LXA4), and leukotriene B4 (LTB4) levels in the ipsilateral hind paw from adjuvant-induced
arthritis rats. a; PGE2, b; LXA4, c; LTB4. Data are means ± SD. *p < 0.05 versus ADV+/CON diet group (n = 10 per group).
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and DHA metabolism might be modified by chronic in-
flammation. The reason is unclear at this stage.
Considering the reason why dietary ARA did not affect
AIA severity, it is important to examine the changes in
lipid mediators from ARA. This is the first study to
demonstrate a relationship between ARA composition
and ARA-derived lipid mediators in an AIA model. In
particular, PGE2 is well known to be a proinflammatory
cytokine for various types of inflammation and a key fac-
tor in RA. In fact, NSAIDs have been one of the import-
ant pharmaceutical treatments against RA due to their
suppression of PGE2 formation through COX inhibition
[1,22,23]. The COX-PGE2 axis dependency was con-
firmed also in the present results, that is, an 8-time ele-
vation of paw PGE2 content was evoked by arthritis
induction, and indomethacin treatment clearly sup-
pressed PGE2 production and AIA parameters (Figure 6).
Surprisingly, the PGE2 content in the paw was not in-
creased in either the ARA(L), ARA(M), or ARA(H)
groups, although the ARA content in the paw was
significantly increased in a dose-dependent manner
(Figure 2). These findings may seem unreasonable be-
cause ARA is a precursor of PGE2. However, in the pre-
vious studies, dietary ARA did not affect the content ofPGE2 and/or its metabolites in serum and urine in
healthy human participants [12] and in the colon of a
murine colitis model [14]. Taken together, it is suggested
that dietary ARA does not affect the PGE2 content
in vivo, and that lack of elevation of the PGE2 content is
one of the reasons for no change in arthritis severity.
These hypotheses are also supported by the correlation
results for PGE2 and arthritis parameters (Figure 7), and
seem to be different to the results of previous ex vivo or
in vitro studies which indicated an increase in eicosanoid
production with ARA level [15-17,36]. The reasons for
these differences are unclear, but may be related to the
fact that intensive and unphysiological stimuli are used
in ex vivo or in vitro experiments. PGE2 metabolism
may be also involved. Ex vivo or in vitro experimental
conditions for PGE2 production may need to be carefully
considered to understand in vivo situations.
Another ARA-derived lipid mediator, LXA4, is produced
by 15- and 5-lipoxygenases and is clarified to have an
anti-inflammatory role [37]. In the animal arthritis
model, 12/15-lipoxigenase–deficient mice showed en-
hanced inflammatory effects and decreased levels of
LXA4 [38], and a lipoxin receptor agonist could modu-
late the immune response and reduce the severity of




















































































Figure 7 Correlation analysis. Correlation analyses were performed between the ARA content of the ipsilateral hind paw versus paw edema
(disease marker) (a), PGE2 content (b), and between paw edema versus PGE2 contents (c). ●; ADV+/CON, △; ADV+/ARA(L), ◇; ADV+/ARA(M),
☐; ADV+/ARA(H).
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pared with the control group but no significant differ-
ences or dose-dependency was found (Figure 6),
although dietary ARA increased the LXA4 content in
the colon in our previous study using a murine colitis
model [14]. These results suggest that the effects of
dietary ARA on LXA4 production differ depending on
the inflammation model. LTB4, one of the major leuko-
trienes, was shown to be produced in the joints of RA
patients [40,41]. In the present study, the LTB4 content
in the paw tended to be increased by arthritis induc-
tion and were not affected by dietary ARA. These re-
sults are similar to those for the colitis model [14], and
suggest that dietary ARA has little effect on LTB4
production.
Gene expression of COX-1 and COX-2 is related to
PGE2 synthesis, that of 15-LOX and 5-LOX is related toLXA4 and LTB4 synthesis, and that of cPLA2 is related
to all of these mediators through release of ARA from
membrane phospholipids. Gene expression of these medi-
ators was unchanged by dietary ARA (Additional file 5:
Figure S4). This is consistent with the results showing that
the PGE2, LXA4, and LTB4 contents were unchanged by
dietary ARA (Figure 6). However, because we could not
observe increases in gene expression by arthritis induction
except for COX-1, we cannot draw a firm conclusion
about its effects on gene expression. Further studies, for
example a time course experiment [42,43], are necessary
to determine the effects of dietary ARA on gene expres-
sion related to lipid mediators. These results are similar
to the case of gene expression of inflammatory cytokines.
In the present study, dietary ARA did not affect the gene
expressions of these cytokines in vivo (Additional file 6:
Figure S5). However, we could not observe increases of
Tateishi et al. Lipids in Health and Disease 2015, 14:3 Page 9 of 11
http://www.lipidworld.com/content/14/1/3gene expression by arthritis induction, and further studies
are needed to determine the effect of dietary ARA on gene
expression of inflammatory cytokines.
In this study, we showed the amounts of lipid media-
tors in paws, but their contribution to the disease state
is not fully confirmed. Although PGE2, LXA4 and LTB4
are known to be important as described above, it re-
mains unclear whether their contents in the present ex-
periment are enough to show physiological/pathological
activities or not. It may be revealed by local injection of
PGE2, LXA4 and LTB4 or the specific antagonists for ex-
ample. The amount of lipid peroxides, free radical gener-
ation and anti-oxidant content in the tissues and cells
might help the clarification. Furthermore, it has been
well-known that lipid mediators might affect the amount
of TGF-β beta [44]. The cytokine profile is also expected
to be clarified by further studies.
DHA, EPA, or fish oil was reported to be effective against
arthritis in both animal and clinical studies [31-34,45],
while some studies failed to show any benefit [32,46]. In
the present study, DHA administration significantly in-
creased the contents of DHA and EPA in the paw, but
did not affect either inflammatory parameters or the
amounts of PGE2, LXA4, and LTB4. One of the reasons
may be that the experimental diets in the present study
were designed to have similar n-6/n-3 ratio, and that
therefore n-6/n-3 ratio was almost the same in the con-
trol (2.0) and DHA (2.2) diets. The n-6/n-3 ratios in the
previous studies seem different between the control and
DHA, EPA or fish oil groups or unclear [31-34], and it
might cause the difference of DHA efficacy.
To the best of our knowledge, there is one study in 1997
regarding the effects of ARA on AIA in essential fatty
acid-deficient (EFAD) rats. ARA supplementation could
increase the ARA content in EFAD and recover the sup-
pressed inflammatory response in EFAD rats compared
with normal rats [47]. This was an early and important re-
port, but it does not necessarily reflect the situation for
general arthritis. The fatty acid profile in EFAD is quite
abnormal, that is, ARA and LA are extremely reduced.
Furthermore, Mead acid, which was clarified to have anti-
inflammatory properties [48-50], was endogenously syn-
thesized instead of ARA in EFAD and was reduced by
ARA administration [47]. It is also reported that Mead
acid is detected in articular cartilage of newborn animals,
suggesting that Mead acid might have unknown roles in
cartilage development [51]. Therefore, it is difficult to esti-
mate the effects of ARA on AIA from the previous report
under the EFAD condition.
Dietary ARA intakes for the ARA(L), ARA(M), and
ARA(H) groups were estimated to be approximately 35,
73, and 156 mg/kg/day, respectively, on the assumption
that rats consumed a diet about 10% of their body
weight daily. In humans, the average ARA intake fromdaily foods is approximately 150–200 mg ARA per day
[52]. Compared to the ARA intake of humans, the ARA
doses used in the present study are markedly higher.
The results in the present study may thus be regarded as
those under excess ARA administration.Conclusion
Dietary ARA supplementation significantly increased the
content of ARA in the inflamed paw in a dose-
dependent manner, but did not affect arthritis inflamma-
tory parameters or the content of lipid mediators in an
AIA rat model.Additional files
Additional file 1: Table S1. Arthritis induction by various doses of
M. butyricum.
Additional file 2: Figure S1. Fatty acid content of phospholipids ((a)
ARA, (b) LA, (c) DHA, and (d) EPA) in the plasma from adjuvant-induced
arthritis rats. Data are means ± SD. *p < 0.05, **p < 0.01 versus ADV+/CON
diet group (n = 10 per group).
Additional file 3: Figure S2. Total n-6, total n-3 and n-6/n-3 ratio on
fatty acid content of phospholipids in the paw (a, b, c) or plasma (d, e, f)
from adjuvant-induced arthritis rats. Data are means ± SD. *p < 0.05,
**p < 0.01 versus ADV+/CON diet group (n = 10 per group).
Additional file 4: Figure S3. Body weight change before and after
arthritis induction. Rats were fed three types of ARA diet (ARA(L), ARA(M),
or ARA(H)), DHA diet, or control diet (CON) from day 0. Adjuvant arthritis
was induced by subcutaneous injection of adjuvant containing 0.05 mg
of M. butyricum (ADV+) or without M. butyricum (ADV-) on day 29. The IM
group rats were orally administered indomethacin (1mgkg−1) once daily
from day 29 to day 56. Data are means ± SD. **p < 0.01 versus ADV+/CON
diet group (n = 10 per group).
Additional file 5: Figure S4. Expression of genes related to lipid
mediator formation. cPLA2 (a), COX-1 (b), COX-2 (c), 5-LOX (d) and 15-LOX
(e) in the ipsilateral hind paw from adjuvant-induced arthritis rats fed CON,
ARA(L), ARA(M), ARA(H) and DHA diet. Data are means ± SD. **p < 0.01
versus ADV+/CON diet group (n = 10 per group).
Additional file 6: Figure S5. Expression of genes related to
inflammation. IL-1beta (a), IL-6 (b), TNF-α (c), and IL-10 (d) in the ipsilateral
hind paw from adjuvant-induced arthritis rats fed a CON, ARA(L), ARA(M),
ARA(H), and DHA diet (n = 10 per group). Data are means ± SD.Competing interests
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